Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross‐disease cohort study

BACKGROUND: The use of rifampicin for cholestatic pruritus is accompanied by concerns over safety, but the availability of real‐world prescribing data is relatively limited. AIM: We sought to describe the rate and characteristics of rifampicin‐induced hepatitis in a mixed aetiology cohort of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, G. J., Rahman, S. R., Levy, C., Hirschfield, G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Safety of Rifampicin in Treatment of Cholestatic Pruritus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900962/
https://www.ncbi.nlm.nih.gov/pubmed/29468705
http://dx.doi.org/10.1111/apt.14579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900962/
https://www.ncbi.nlm.nih.gov/pubmed/29468705
http://dx.doi.org/10.1111/apt.14579

Ejemplares similares